Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06162221 · ClinicalTrials.gov registry record · Phase 1
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
A Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and KRAS, NRAS, HRAS-mutated NSCLC, sponsored by Revolution Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 616
- Enrollment target
- 20
- Study locations
NCT06162221: Recruiting Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and KRAS, NRAS, HRAS-mutated NSCLC, sponsored by Revolution Medicines.
NCT06162221 is a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and KRAS, NRAS, HRAS-mutated NSCLC that is actively recruiting participants, run by Revolution Medicines. The registered enrollment target is 616 participants, above the 275-participant average among 59 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (124% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06162221, a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and KRAS, NRAS, HRAS-mutated NSCLC, is actively recruiting participants, sponsored by Revolution Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 616 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other. The first four subprotocols include the following: Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805
Primary Outcome
Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs and clinically significant changes in laboratory values, ECGs and vital signs
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG RMC-6291
- DRUG RMC-6236
Study Locations (20)
California
- City of Hope - Duarte - Duarte
- City of Hope - Lennar - Irvine
- UC Davis, Davis Comprehensive Cancer Center - Sacramento
- University of California, San Diego Moores Cancer Center - San Diego
- UCSF Medical Center - Mission Bay - San Francisco
- Stanford University - Stanford Cancer Institute - Stanford
New York
- New York University Langone Health - New York
- Icahn School of Medicine at Mount Sinai - New York
- Columbia University Medical Center - New York
- Clinical Research Alliance - Westbury
Florida
- Boca Raton Clinical Research Associates - Plantation
- Cancer Specialists of North Florida - Saint Augustine
- H Lee Moffitt Cancer Center and Research Institute - Tampa
Arizona
- Banner MD Anderson Cancer Center - Gilbert
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion) - Detroit
Montana
- Intermountain Health - St. Vincent Frontier Cancer Center - Billings
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 616 participants |
| Start Date | 2024-01-18 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
What NCT06162221 shows while recruiting
NCT06162221 is an interventional study that assigns participants to a tested intervention. The registered 616 participants enrollment target is mid-sized for trials with a published cap, above the 275-participant average among 59 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (124% higher).
The record links to 5 conditions, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06162221 names 20 study sites across 10 states, led by California, New York, Florida.
Frequently Asked Questions
What is clinical trial NCT06162221 about?
NCT06162221 is a clinical study titled "Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC". The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other. The first four subprotocols include the following: Subpr...
What is the current status of trial NCT06162221?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 616 participants. The study started on 2024-01-18. Estimated completion is 2028-12.
What conditions does trial NCT06162221 study?
This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC), KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer, RAS G12D-mutated NSCLC.
What interventions are being tested in trial NCT06162221?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Cisplatin (DRUG), RMC-6291 (DRUG), RMC-6236 (DRUG).
Who is sponsoring clinical trial NCT06162221?
This trial is sponsored by Revolution Medicines, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06162221 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-small Cell Lung Cancer (NSCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06162221's enrollment target sits among peer trials
616 7th of 59 higher than 53 of 59 other Non-small Cell Lung Cancer (NSCLC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-small Cell Lung Cancer (NSCLC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04813185 · 616 participants · NA
Preventing Retaliatory Gun Violence in Violently Injured Adults
- NCT06105957 · 616 participants · NA
Optimal Digital Weight Loss Treatment for Rural Individuals
- NCT02610179 · 617 participants · NA
Strawberry Candy Twists as an Alternative Screen for Gestational Diabetes: A Prospective Trial
- NCT06593652 · 615 participants · NA
Evaluating Caregiver Involvement in Primary Care-Based Brief Interventions for Adolescent Alcohol Use Problems
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI